Global Apheresis Market

Apheresis Market Size, Share, Growth Analysis, By Device(Leukapheresis, plasmapheresis, plateletpheresis, erythrocytapheresis), By Technology(Centrifugation and membrane separation), By Application(Renal disorders, hematological disorders, neurological disorders, autoimmune disorders), By Region - Industry Forecast 2024-2031

Report ID: SQMIG35D2190 | Region: Global | Published Date: February, 2024
Pages: 157 | Tables: 92 | Figures: 76

Apheresis Market Competitive Landscape

The market is moderately competitive, with a few major players dominating the industry. While the market has established a strong presence in many regions and demonstrated initial success, its full potential in developing regions is yet to be fully realized. The growth of the market is being propelled by increasing government initiatives and a rising awareness among people about the condition. This heightened awareness is driving the demand for advanced treatments and therapies in the market.

Apheresis Market Top Player’s Company Profiles

  • B. Braun SE (Germany)
  • Asahi Kasei Corporation (Japan)
  • Fresenius SE & Co. KGAA (Germany)
  • Terumo Corporation (Terumo BCT Inc.) (Japan)
  • Grifols (Spain)
  • CSL Behring (Australia)
  • Octapharma (Switzerland)
  • Kedrion (Italy)
  • Pfizer Inc. (United States)
  • Baxter International Inc. (United States)
  • Bayer AG (Germany)
  • BioMarin Pharmaceutical Inc. (United States)
  • Roche (Chugai Pharmaceutical Co.) (Switzerland/Japan)
  • Sanofi (France)
  • Takeda Pharmaceutical (Japan)
  • Novo Nordisk (Denmark)
  • Biogen (United States)
  • Shire (Ireland)
  • Grifols (Spain)
  • Kogenate (Germany)

Apheresis Market

$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Apheresis Market size was valued at USD 2.79 billion in 2022 and is poised to grow from USD 3.10 billion in 2023 to USD 7.22 billion by 2031, at a CAGR of 11.15% during the forecast period (2024-2031).

The market is moderately competitive, with a few major players dominating the industry. While the market has established a strong presence in many regions and demonstrated initial success, its full potential in developing regions is yet to be fully realized. The growth of the market is being propelled by increasing government initiatives and a rising awareness among people about the condition. This heightened awareness is driving the demand for advanced treatments and therapies in the market. 'B. Braun SE (Germany)', 'Asahi Kasei Corporation (Japan)', 'Fresenius SE & Co. KGAA (Germany)', 'Terumo Corporation (Terumo BCT Inc.) (Japan)', 'Grifols (Spain)', 'CSL Behring (Australia)', 'Octapharma (Switzerland)', 'Kedrion (Italy)', 'Pfizer Inc. (United States)', 'Baxter International Inc. (United States)', 'Bayer AG (Germany)', 'BioMarin Pharmaceutical Inc. (United States)', 'Roche (Chugai Pharmaceutical Co.) (Switzerland/Japan)', 'Sanofi (France)', 'Takeda Pharmaceutical (Japan)', 'Novo Nordisk (Denmark)', 'Biogen (United States)', 'Shire (Ireland)', 'Grifols (Spain)', 'Kogenate (Germany)'

The rising incidence of chronic diseases such as cancer, autoimmune disorders, and cardiovascular diseases is driving the demand for apheresis procedures. Apheresis plays a crucial role in managing these conditions by selectively removing or collecting specific blood components, thereby improving patient outcomes.

One key market trend in the apheresis market is the increasing adoption of personalized medicine and targeted therapies. As healthcare advancements continue to evolve, there is a growing emphasis on tailoring treatments to individual patients based on their specific medical conditions, genetic profiles, and treatment responses. This approach allows for precise and customized treatment regimens, optimizing therapeutic outcomes and improving patient care.

The dominating region in the global apheresis market is North America. North America boasts a significant market share due to several factors. The region has a well-established healthcare infrastructure, advanced technological capabilities, and a high prevalence of chronic diseases that require apheresis procedures. Moreover, favorable reimbursement policies and strong awareness about the benefits of apheresis therapies contribute to the region's dominance. North America is home to key market players, cutting-edge research facilities, and a supportive regulatory framework, all of which further drive the market's growth in the region. These factors combined make North America the leading and dominating region in the global apheresis market.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

Click here right-arrow
logo-images

Related Reports

Plasmapheresis Market
Buy Now GET FREE SAMPLE
Leukapheresis Market
Buy Now GET FREE SAMPLE
Plasma Therapy Market
Buy Now GET FREE SAMPLE
Orthobiologics Market
Buy Now GET FREE SAMPLE
Apoptosis Assay Market
Buy Now GET FREE SAMPLE
Hyperphosphatemia Therapeutics Market
Buy Now GET FREE SAMPLE
Biopreservation Market
Buy Now GET FREE SAMPLE
Electrophysiology Market
Buy Now GET FREE SAMPLE

Feedback From Our Clients

Global Apheresis Market

Report ID: SQMIG35D2190

$5,300
BUY NOW GET FREE SAMPLE